Business
KEYTRUDA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program. Opportunities lie in label expansion, combination therapies, and emerging markets, with sustained leadership in immuno-oncology.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "KEYTRUDA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides
About this update from Merck & Company, Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program. Opportunities lie in label expansion, combination therapies, and emerging markets, with sustained leadership in immuno-oncology.","length":324,"tagName":"p"},{"type":"text","content":"Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "KEYTRUDA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.","length":170,"tagName":"p"},{"type":"text","content":"The report provides insights into KEYTRUDA for approved indications like NSCLC and solid tumors, and potential ones such as GBM and multiple myeloma. It details KEYTRUDA's sales forecast, market potential, and developmental activities across major markets such as the US, EU5, and Japan. The analysis includes SWOT, market competitors, and emerging therapies.","length":363,"tagName":"p"},{"type":"text","content":"KEYTRUDA Drug Summary","length":21,"tagName":"p"},{"type":"text","content":"KEYTRUDA (Pembrolizumab) is an immune checkpoint inhibitor blocking PD-1 to restore anti-tumor responses. Highly effective across cancers like NSCLC and melanoma, it's a frontrunner in immuno-oncology for durable responses and improved survival. Sold globally, it is administered via infusion and can be combined with other therapies based on cancer type and biomarker status.","length":380,"tagName":"p"},{"type":"text","content":"Key Factors Driving KEYTRUDA Growth 1. Unmatched Commercial Scale and Sustained Revenue Growth","length":94,"tag...